Asia Executives To Watch: GSK Japan Names Startup Founder VP, Daiichi's New Overseas Division
The spring cherry blossom has ushered in a flurry of new executives to the industry in the Asia Pacific, particularly in Japan where the new fiscal years starts in April for most companies. GSK has taken a bold step to appoint an executive with a previous startup background to its senior leadership in Japan, while Daiichi Sankyo has set up a special division for overseas expansion. Nippon Shinyaku and IQVIA Japan have also made new appointments.
You may also be interested in...
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.
From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.